Key Takeaways
- U.S. crude futures tumbled $2.13 to $74.66 a barrel following the signing of a landmark interim peace agreement between the U.S. and Iran, signaling an end to months of maritime blockades.
- NATO Secretary-General Mark Rutte confirmed that the U.S. is immediately scaling back its participation in crisis response forces, shifting the conventional defense burden to European allies and Canada.
- Russia reported destroying 555 Ukrainian drones in a massive overnight engagement that disrupted traffic near a Moscow oil refinery and highlighted escalating aerial warfare.
- Roche (RHHBY) received FDA acceptance for its sBLA for a Lunsumio-Polivy combination therapy, targeting large B-cell lymphoma with a regulatory decision expected by February 9, 2027.
- Ukrainian President Volodymyr Zelenskiy is set to attend high-level alliance meetings in Brussels this Thursday to coordinate defense aid and seek licenses for air defense production.
Energy Markets: U.S.-Iran Accord Triggers Price Slump
Oil prices experienced a sharp decline on Thursday as the global energy complex reacted to the formal signing of a memorandum of understanding between the United States and Iran. U.S. West Texas Intermediate (WTI) crude futures dropped $2.13 to $74.66 a barrel, while Brent crude fell approximately 1.6% to trade near $78.43. The agreement, signed electronically and witnessed by international diplomats, is expected to lead to the reopening of the Strait of Hormuz by Friday, June 19.
The diplomatic breakthrough effectively ends a three-and-a-half-month disruption that had removed nearly one-fifth of the world's petroleum liquid supplies from the market. While President Donald Trump warned that military action could resume if Tehran fails to comply with the terms, market participants are heavily pricing in the return of Iranian maritime trade. This shift has also bolstered Asian equity markets, with Japan's Nikkei 225 hitting an all-time high on hopes of stabilized energy supply chains.
Defense: NATO Restructures as U.S. Pulls Back
In Brussels, NATO Secretary-General Mark Rutte announced that the U.S. has begun an immediate reduction of its commitments to the alliance's crisis response forces. The "adjustments" involve a significant scaling down of U.S. military assets—including fighter jets, refueling aircraft, and carrier groups—designated for European defense plans. Rutte emphasized that while the U.S. remains a security pillar, European allies must now fill these capability gaps to ensure collective security under Article 5.
Amidst this structural shift, President Volodymyr Zelenskiy arrived in Brussels for the European Council summit and Ramstein group meetings. Zelenskiy is reportedly seeking $20 billion in additional military funding and U.S. licenses to produce advanced air defense systems domestically. The timing is critical, as Russia’s Defense Ministry claimed its air defenses intercepted a record 555 Ukrainian drones overnight, a barrage that forced the partial closure of Moscow's ring road.
Healthcare: Roche Secures FDA Priority for Lymphoma Combo
On the corporate front, Roche (RHHBY) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Lunsumio (mosunetuzumab) combined with Polivy (polatuzumab vedotin). The application targets adult patients with relapsed or refractory large B-cell lymphoma (LBCL) who have received at least one prior therapy. The FDA has set a target action date of February 9, 2027, for its regulatory decision.
The filing is supported by data from the Phase III SUNMO study, which demonstrated a 59% reduction in the risk of disease progression or death compared to standard chemo-immunotherapy. The combination therapy showed a median progression-free survival of 11.5 months, nearly triple the 3.8 months observed in the control group. If approved, this subcutaneous, "outpatient-ready" regimen could significantly expand access to care in community settings for patients with aggressive lymphoma.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.